Abstract:Introduction: Growing evidence suggests a link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded RV, and mortality in pulmonary arterial hypertension (PAH). However, there are no currently available therapies that specifically target RV fibrosis. Using RV tissues from a preclinical rat PAH model, we previously reported that activation of stress-responsive protein kinase D (PKD) and phosphorylation of its substrate dynamin-related protein 1 (DRP1) occur specifically at the outer mitochondrial membrane (OMM) of RV cardiac fibroblasts (RV-CFs), but not in RV myocytes. RV-CFs isolated from PAH rats exhibited increased mitochondrial fission, mitochondrial reactive oxygen species (mROS), and proliferative signaling compared to RV-CFs from control animals, suggesting an association between PKD signaling in RV-CFs and RV fibrosis. Hypothesis: Inhibition of mitochondrial PKD signaling in CFs can attenuate RV fibrosis in PAH. Methods: Primary adult CFs from human ventricles were used for in vitro assays. A preclinical rat PAH model (Sugen 5416 injection and 3-week hypoxia followed by 4-week normoxia) was used for in vivo assays. Results: To specifically inhibit PKD activity at the OMM, an OMM-targeted dominant-negative PKD1 (mt-PKD-DN) was generated by adding an OMM-target sequence (amino acid 1-33 from human TOM20) at the N-terminus of PKD1-K612W. We confirmed that mt-PKD-DN is specifically expressed in mitochondria and decreases basal PKD activity only in mitochondria, assessed by protein fractionation. Importantly, mt-PKD-DN was able to inhibit mitochondrial fission, reduce mROS, hyperpolarize mitochondrial membrane potential, and ultimately decrease CF proliferation in vitro. To inhibit mitochondrial PKD activity in quiescent and resident CFs in vivo, we next administrated CF-selective adeno-associated virus serotype 9 (AAV9) carrying human TCF21 (hTCF21) promoter and mt-PKD-DN into the rat PAH model by tail vein injection. Introduction of AAV9-hTCF21-mt-PKD-DN or its control virus did not significantly alter baseline cardiac function. CF-specific mt-PKD-DN expression was able to significantly reduce RV hypertrophy/fibrosis, and RV-CF hyperproliferation as assessed by immunostaining of a nucleus-localized marker of active cell proliferation Ki67. Lastly, we found the partial recovery of in vivo RV function (i.e., recovery of tricuspid annular plane systolic excursion in echocardiography) in PAH rats with mt-PKD-DN. Conclusion: Targeting mitochondrial PKD may be a potential therapeutic strategy to reduce cardiac fibrosis under pathological conditions including PAH. R01HL136757 (to J.O.-U), AHA 18CDA34110091 (to B.S.J) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

Voltage-dependent anion channel 1 (VDAC1) overexpression alleviates cardiac fibroblast activation in cardiac fibrosis via regulating fatty acid metabolism

Abstract P467: Cardiac-specific Deletion Of Voltage Dependent Anion Channel 2 Leads To Dilated Cardiomyopathy By Altering Calcium Homeostasis

Attenuating persistent sodium current–induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress

A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury

IP3R1/GRP75/VDAC1 complex mediates endoplasmic reticulum stress-mitochondrial oxidative stress in diabetic atrial remodeling

Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice

Aorta-on-a-chip reveals impaired mitochondrial dynamics as a therapeutic target for aortic aneurysm in bicuspid aortic valve disease

Effect of the Angiotensin II Receptor Blocker Valsartan on Cardiac Hypertrophy and Myocardial Histone Deacetylase Expression in Rats with Aortic Constriction

Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease

Protective Effects of Dapagliflozin on the Vulnerability of Ventricular Arrhythmia in Rats with Pulmonary Artery Hypertension Induced by Monocrotaline

High-throughput proteomic analysis unveils metabolic and mitochondrial signaling rewiring by chronic ivabradine treatment in duchenne muscular dystrophy

Activation of NADPH Oxidase Mediates Mitochondrial Oxidative Stress and Atrial Remodeling in Diabetic Rabbits

Myocardial Aldosterone Receptor and Aquaporin 1 Up-Regulation Is Associated with Cardiomyocyte Remodeling in Human Heart Failure

Effects Of Endothelin-1 Chronic Stimulation On Electrical Restitution, Beat-To-Beat Variability Of Repolarization, And Ventricular Arrhythmogenesis

Role of mitochondrial PKD on right ventricular fibrosis under pulmonary hypertension

Effect of Atorvastatin on Aldosterone Induced Myocardial Fibrosis in A Rat Model and Its Potential Mechanism

Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology

Effect And Mechanism Of Sacubitril/Valsartan On Ventricular Remodeling In Diabetic Rats With Cardiomyopathy

Effect of Calcium-Sensing Receptor Inhibition on the Vulnerability of Ventricular Arrhythmia in a Rat Model of Chronic Heart Failure